CurrentRheuma — Rheumatoid arthritis

Glucocorticoid purchases and methotrexate persistence in early rheumatoid arthritis in Finland

2026-11-13T17:28:41.089Z

Research article · Scand J Rheumatol, 2026.

Validation of rheumatoid arthritis low inflammatory activity: a novel clinical target quantifying inflammatory disease activity

2026-11-13T06:15:29.260Z

Diagnostic or prognostic study · Ann Rheum Dis, 2026.

Associations between pharyngitis, tonsillitis, and incident rheumatic diseases

2026-11-05T16:08:02.128Z

Case-control study · Semin Arthritis Rheum, 2026.

ALDH4A1 and anti-ALDH4A1 emerge as a novel antigenic axis linked to atherosclerosis in rheumatoid arthritis

2026-11-05T13:24:18.717Z

Cohort study · Rheumatology (Oxford), 2026.

Better After CHoosing in rheumatoid arthritis (the BACH trial): patients who have the opportunity to choose their treatment are more satisfied

2026-11-05T13:24:18.717Z

Randomized controlled trial · RMD Open, 2026.

Comparative effectiveness and safety of five Janus kinase inhibitors in real-world clinical practice: the multicentre ANSWER cohort

2026-11-05T13:24:18.717Z

Cohort study · Rheumatology (Oxford), 2026.

Frequency and predictors of disease progression in contemporary ACPA-negative undifferentiated arthritis in a treated-to-target early arthritis clinic

2026-11-05T13:24:18.717Z

Research article · RMD Open, 2026.

Real-world association of biologic and targeted synthetic DMARD use with mortality in rheumatoid arthritis-associated interstitial lung disease: a nationwide cohort study

2026-11-05T13:24:18.717Z

Cohort study · RMD Open, 2026.

Title: Impact of Coexisting Gout on Disease Activity in Rheumatoid Arthritis: Data from the Ontario Best Practices Research Initiative (OBRI)

2026-11-05T13:24:18.717Z

Cohort study · Joint Bone Spine, 2026.

Transformative improvement with staggered gains in rheumatoid arthritis remission and sustained remission, but higher relapse rates: a population-based cohort study from 1990 to 2019

2026-11-05T13:24:18.717Z

Cohort study · RMD Open, 2026.

Childhood Adversity and Self-Reported Rheumatoid Arthritis: A Structural Equation Modeling Analysis of the Canadian Longitudinal Study on Aging

2026-11-05T13:10:58.883Z

Research article · J Rheumatol, 2026.

Diffuse large B cell lymphoma in rheumatoid arthritis express polyreactive and autoreactive BCRs binding protein modifications

2026-11-05T13:10:58.883Z

Cohort study · Arthritis Res Ther, 2026.

Five items are sufficient to assess rheumatoid arthritis disease activity by patient reported outcome measure: a computer adaptive test simulation study

2026-11-05T13:10:58.883Z

Research article · Rheumatology (Oxford), 2026.

Type I interferon activation in classical monocytes and GZMK+ CD8+ T cells characterises the ultrasound-negative phase of imminent rheumatoid arthritis

2026-11-05T13:10:58.883Z

Research article · Ann Rheum Dis, 2026.

Incidence of Interstitial Lung Disease in Patients With Rheumatoid Arthritis Treated With Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs

2026-11-04T23:58:57.553Z

Cohort study · JAMA Netw Open, 2023. ILD, crude IR per 1000 person-years; adjusted risk vs adalimumab: Adalimumab 3.43 (95% CI 2.85-4.09) per 1000 person-years · Abatacept 4.46 (95% CI 3.44-5.70) per 1000 person-years · Rituximab 6.15 (95% CI 4.76-7.84) per 1000 person-years · Tocilizumab 5.05 (95% CI 3.47-7.12) per 1000 person-years · Tofacitinib 1.47 (95% CI 0.54-3.27) per 1000 person-years

Can biomarkers predict successful tapering of conventional disease-modifying therapy in rheumatoid arthritis patients in stable remission?

2026-11-04T23:43:54.165Z

Cohort study · Clin Exp Rheumatol, 2022. Clinical remission, 12 months: Tapering 64% · Stable treatment 80%

Can numerical rating scales of disease impact be used as targets for patient-centred management in rheumatoid arthritis?

2026-11-04T23:43:54.165Z

Cohort study · Clin Exp Rheumatol, 2022. Dispersion of targets wide CV>0.68

Clinical significance of a self-reported familial occurrence of rheumatoid arthritis among patients with recent-onset arthritis: data from the ESPOIR cohort

2026-11-04T23:43:54.165Z

Cohort study · Clin Exp Rheumatol, 2022. Initiation of a targeted DMARD over time — Familial RA vs No familial RA: HR 1.57 (95% CI 1.1-2.21); p = 0.01; unadjusted

Diagnosis of COVID-19 associated arthritis in patients with or without underlying rheumatic and musculoskeletal disease supported by musculoskeletal ultrasound: a case series from three European centres

2026-11-04T23:43:54.165Z

Cohort study · Clin Exp Rheumatol, 2022. Forms of COVID-19 associated arthritis (clinical and MSUS): Without RMD: polyarticular arthralgia during severe COVID-19, swelling rarely seen, MSUS arthritis only in a few joints affected 2

Disease activity in patients with rheumatoid arthritis increases serum levels of apolipoprotein C-III

2026-11-04T23:43:54.165Z

Cross-sectional study · Clin Exp Rheumatol, 2021. Serum ApoC3 levels by disease activity (adjusted for confounders) — Moderate or high disease activity vs Remission: beta coefficient 1.28 mg/dl (95% CI 0.16-2.39); p=0.025; adjusted for confounders

MicroRNA and interleukin 6 interplay in the adipose tissue of rheumatoid arthritis patients

2026-11-04T23:43:54.165Z

Mechanistic study · Clin Exp Rheumatol, 2021. differentially expressed (DE) miRs between AT with high and low IL-6 mRNA 30

New onset and flare of rheumatic diseases following COVID-19 vaccination are mild and respond well to treatment: 9-month follow-up data from a single centre cohort

2026-11-04T23:43:54.165Z

Cohort study · Clin Exp Rheumatol, 2021. RD following COVID-19 vaccination: onset, manifestations and response to therapy: New onsets 24 (80.0%) · Flares 6 (20.0%)

Real-world data on seropositive rheumatoid arthritis, then and now: ten-year outcomes of 1151 patients diagnosed between 1997 and 2011

2026-11-04T23:43:54.165Z

Cohort study · Clin Exp Rheumatol, 2022. DAS28, median (IQR), 10 years: 1997-1999 median 2.9 (IQR 2.2, 3.7) · 2009-2011 median 2.3 (IQR 1.4, 3.0)

Risk of malignant melanoma and non-melanoma skin cancer in rheumatoid arthritis patients initiating methotrexate versus hydroxychloroquine: a cohort study

2026-11-04T23:43:54.165Z

Cohort study · Clin Exp Rheumatol, 2022. Any skin cancer, mean follow-up 388 days: Methotrexate IR 26.21 /1,000 person-years · Hydroxychloroquine IR 25.20 /1,000 person-years

Switching from intravenous tocilizumab to subcutaneous administration during COVID-19 pandemic: impact on treatment efficacy and patient satisfaction

2026-11-04T23:43:54.165Z

Cohort study · Clin Exp Rheumatol, 2022. SC TCZ 26 (70%)

Waning humoral immunity of SARS-CoV-2 vaccination in a rheumatoid arthritis cohort and the benefits of a vaccine booster dose

2026-11-04T23:43:54.165Z

Cohort study · Clin Exp Rheumatol, 2022. Anti-SARS-CoV-2 spike-specific IgG titres: Significant decrease in titres between 1-month and 3-month postvaccination p<0.01

Prevalence, mortality, and treatment of patients with rheumatoid arthritis: A cohort study of the French National Health Data System, 2010–2019

2026-11-04T23:42:37.367Z

Cohort study · Joint Bone Spine, 2022. Overall crude prevalence of RA, 2019: Women 0.66% · Men 0.28%

Characteristics of participants and decliners from a randomized controlled trial on physical activity in patients with rheumatoid arthritis: a retrospective register-based cross-sectional study

2026-11-04T23:40:51.898Z

Cross-sectional study · Scand J Rheumatol, 2021. Sociodemographic, clinical and lifestyle factors in participants vs non-participants, and their association with participation: Declined participation in the JR-SB study 467 (58%)

Clinical evaluation of optical spectral transmission imaging for detection of disease activity in rheumatoid arthritis

2026-11-04T23:40:51.898Z

Diagnostic or prognostic study · Scand J Rheumatol, 2023. OST score: RA median 16.9 (IQR 12.77-19.7) · Controls median 12.11 (IQR 10.32-14.93)

Cost-effectiveness of a telehealth intervention in rheumatoid arthritis: economic evaluation of the Telehealth in RA (TeRA) randomized controlled trial

2026-11-04T23:40:51.898Z

Randomized controlled trial · Scand J Rheumatol, 2022. Cost-effectiveness (willingness to accept a QALY loss) — PRO-TR vs Control: willingness to accept a QALY loss 89 328 EUR

Elevated Fab glycosylation of anti-hinge antibodies

2026-11-04T23:40:51.898Z

Cross-sectional study · Scand J Rheumatol, 2021. AHA reactivity detected for all hinge neoepitopes in both RA and HCs

Evaluation of an individually tailored smoking-cessation intervention for patients with rheumatoid arthritis in an outpatient clinic

2026-11-04T23:40:51.898Z

Cohort study · Scand J Rheumatol, 2023. Quit smoking (self-reported 7 day abstinence), 24 months: Patients who had quit smoking at 24 months 21%

Increased synovial galectin-3 induce inflammatory fibroblast activation and osteoclastogenesis in patients with rheumatoid arthritis

2026-11-04T23:40:51.898Z

Mechanistic study · Scand J Rheumatol, 2022. Gal-3 in RA: Early and chronic RA had persistently increased plasma Gal-3 vs controls

Rheumatoid cachexia in early rheumatoid arthritis: prevalence and associated variables

2026-11-04T23:40:51.898Z

Cross-sectional study · Scand J Rheumatol, 2021. Prevalence of rheumatoid cachexia: Prevalence of RC 24%

The validity of rheumatoid arthritis diagnoses in Finnish biobanks

2026-11-04T23:40:51.898Z

Diagnostic or prognostic study · Scand J Rheumatol, 2021. PPV of CRHC diagnosis of RA (seropositive and seronegative combined): PPV, CRHC diagnosis of RA 0.82

Validation and characterization of venous thromboembolism diagnoses in the Swedish National Patient Register among patients with rheumatoid arthritis

2026-11-04T23:40:51.898Z

Diagnostic or prognostic study · Scand J Rheumatol, 2022. PPV of VTE diagnosis: PPV, overall VTE diagnosis 95%

Can Patients With Controlled Rheumatoid Arthritis Taper Methotrexate From Targeted Therapy and Sustain Remission? A Systematic Review and Metaanalysis

2026-11-04T23:37:51.551Z

Meta-analysis · J Rheumatol, 2022. Ability to sustain remission — MTX tapered vs MTX continued: pooled RR 0.90 (95% CI 0.84-0.97); 10% reduction in the ability to sustain remission

The Effects of Continuity of Rheumatology Care on Emergency Department Utilization and Hospitalizations for Individuals With Early Rheumatoid Arthritis: A Population-Based Study

2026-11-04T23:37:51.551Z

Cohort study · J Rheumatol, 2023. ED visit rates — Intermediate vs High continuity: RR 1.14 (95% CI 1.08-1.20)

Effects of Aging on Rheumatoid Factor and Anticyclic Citrullinated Peptide Antibody Positivity in Patients With Rheumatoid Arthritis

2026-11-04T23:37:51.551Z

Cross-sectional study · J Rheumatol, 2022. RF positivity by decade of age at diagnosis 80.5%, 84.2%, 81.1%, 78%, 74.6%, 62.6%, 51.4%, P < 0.001

Incidence of Herpes Zoster in Patients With Rheumatoid Arthritis in the United States: A Retrospective Cohort Study

2026-11-04T23:37:51.551Z

Cohort study · J Rheumatol, 2023. Overall IR of HZ: RA 21.5 per 1000 person-years · Non-RA 7.6 per 1000 PY

Investigating Associations Between Access to Rheumatology Care, Treatment, Continuous Care, and Healthcare Utilization and Costs Among Older Individuals With Rheumatoid Arthritis

2026-11-04T23:37:51.551Z

Cohort study · J Rheumatol, 2023. Total direct healthcare costs, multivariable, year 5 — Measures not met vs Measures met: Higher costs, access to rheumatology care not met 20% (95% CI 8-32)

Pain Mechanisms Associated With Disease Activity in Patients With Rheumatoid Arthritis Treated With Disease-Modifying Antirheumatic Drugs: A Regression Tree Analysis

2026-11-04T23:37:51.551Z

Cohort study · J Rheumatol, 2023. Posttreatment DAS28, after DMARD treatment: Group 1 mean 2.8 ± 1.0 · Group 2 mean 3.5 ± 1.0 · Group 3 mean 3.4 ± 1.4 · Group 4 mean 4.6 ± 1.1

Red Cell Distribution Width and Absolute Lymphocyte Count Associate With Biomarkers of Inflammation and Subsequent Mortality in Rheumatoid Arthritis

2026-11-04T23:37:51.551Z

Cohort study · J Rheumatol, 2022. Mortality over 10 years by pre-MTX RDW and ALC: High RDW and low ALC prior to MTX associated with subsequent mortality both P < 0.001

Risk Factors for Dementia in Patients With Incident Rheumatoid Arthritis: A Population-Based Cohort Study

2026-11-04T23:37:51.551Z

Cohort study · J Rheumatol, 2022. Risk factors for incident dementia (adjusted for age, sex, calendar year of RA incidence), median follow-up 8.5 yrs: Older age at RA incidence, HR per 1 year increase 1.14 (95% CI 1.12-1.17)

Trends in Incidence of Chronic Heart Failure in Patients With Rheumatoid Arthritis: A Population-Based Study Validating Different Heart Failure Definitions

2026-11-04T23:37:51.551Z

Cohort study · J Rheumatol, 2023. 10-year cumulative incidence of HF events by any chart-reviewed method, 10 years: 1980s 11.66% (95% CI 7.86-17.29) · 1990s 12.64% (95% CI 9.31-17.17) · 2000s 7.67% (95% CI 5.36-10.97)

Understanding Differences in Patient Descriptions of Rheumatoid Arthritis Flares Using OMERACT Core Domains

2026-11-04T23:37:51.551Z

Cross-sectional study · J Rheumatol, 2023. Characteristics associated with flare descriptions: Fatigue more commonly noted among females, OR 6.12; P < 0.001

Association between risk, duration and cause of hospitalisations in people with rheumatoid arthritis and multimorbidity in the UK Biobank and Scottish Early Rheumatoid Arthritis (SERA) cohorts: Longitudinal observational study

2026-11-04T23:37:28.623Z

Cohort study · Semin Arthritis Rheum, 2022. Hospitalisation rate — RA + ≥ 2 LTCs vs RA only: IRR 2.10 (95% CI 1.91 to 2.30); UK Biobank

Genetic link between rheumatoid arthritis and autoimmune liver diseases: A two-sample Mendelian randomization study

2026-11-04T23:37:28.623Z

Research article · Semin Arthritis Rheum, 2022. RA risk per genetically predicted AILD (inverse-variance weighted (IVW)) — PBC: IVW OR 1.149 (95% CI 1.063-1.241); P<0.001

Humoral and cellular immune responses in persons with rheumatoid arthritis after a third dose of mRNA COVID-19 vaccine

2026-11-04T23:37:28.623Z

Cohort study · Semin Arthritis Rheum, 2023. Normal humoral response (ELISA within 1 SD of healthy control mean), week 4: Normal anti-S response in RA 43%

A scoping review of shared care models for rheumatoid arthritis with patient-initiated follow-up

2026-11-04T23:02:07.938Z

Research article · Semin Arthritis Rheum, 2023. Model implementation varied significantly between studies